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Supplemental Experimental Procedures
Bacterial strains and growth conditions
All bacterial strains and plasmids used in this study are listed in Table S2 . Bacteria were grown in LB media or LB-agar with antibiotics at the following concentrations: ampicillin (Amp) 150 µg/mL; kanamycin (Kan) 50 µg/mL; rifampicin (Rif) 200 "g/mL; spectinomycin (Spc) 100 µg/mL: and tetracycline (Tet) 10 µg/mL. The !rsmE::kan mutation (Baba et al., 2006) was transferred into E. coli strain CH1944 by bacteriophage P1-mediated transduction. E. cloacae genes were deleted using the same protocol as described for E. coli (Hayes et al., 2002) . DNA sequences located upstream and downstream of target genes were amplified and cloned into plasmid pKAN (Hayes et al., 2002) or pSPM (Koskiniemi et al., 2013) to flank kanamycin-or spectinomycin-resistance cassettes, respectively. The resulting plasmids were linearized by restriction endonuclease digestion and electroporated into E. cloacae cells expressing the phage ! Red proteins from plasmid pKOBEG (Chaveroche et al., 2000; Perez et al., 2007) .
The wzb upstream region was amplified with oligonucleotides (restriction sites underlined) ECLwzb(KO)-Sac (5´ -TTT GAG CTC CTG CAG GCG CTG ATG C)/ECL-wzb(KO)-Bam (5´ -TTT GGA TCC GCG GAT TAC CAG GTA TG), and the downstream region with ECL-wzb(KO)-Eco (5´ -TTT GAA TTC CAG CAG GGA TAA CAA TGA C)/ECL-wzb(KO)-Kpn (5´ -TTT GGT ACC CCC TTT CGG CAG CAC). The kanamycin-resistance cassette was removed from the resulting E. cloacae !wzb::kan strain using FLP recombinase as described (Cherepanov and Wackernagel, 1995; Datsenko and Wanner, 2000) . The cdiA (Aiyar et al., 1996) and the final product electroporated into E.
cloacae spc::cdiB cells followed by selection for kanamycin-resistant recombinants. The kanamycinresistance cassette was subsequently removed using FLP recombinase. Finally, the tssM1 (ECL_01536) gene was deleted from the inhibitor cells. The tssM1 upstream region was amplified with primers
ECL-vask1(KO)-Sac (5´-TTT GAG CTC GAA ATC GAC GCC GGT CTG)/ECL-vask1(KO)-
Bam (5´ -TTT GGA TCC TTT CCT TGC GGC AAT CCG); and the downstream region with primers
ECL-vask1(KO)-Eco (5´-TTT GAA TTC CAA GGA CAG CCG TAT GAC)/ECL-vask1(KO)-Kpn (5´ -
TTT GGT ACC GAA TCG ACA TCA GCA TCT C). The resulting construct was electroporated into E.
cloacae spc::cdiB !araBAD cells followed by selection for kanamycin-resistant recombinants.
Protein expression constructs
Protein overproduction constructs were generated using plasmid pET21S (Aoki et al., 2010 ) and its derivative pCH8001, which contains a KpnI restriction site immediately upstream of NcoI. The cdiA-CT/cdiI ECL coding sequence was amplified from E. cloacae genomic DNA using primers ECL-CT-
Kpn/Nco-for (5´ -GGG GGT ACC ATG GCT GAG AAT AAC TCG CTG GC and ECL-cdiI-Nhe-rev (5´ -CTC TGC TAG CGT TGT TAA GAC TAT GAT AAA AAT C). The PCR product was digested with
KpnI/NheI and ligated to KpnI/SpeI-digested pCH8001 to generate plasmid pET21K::cdiA-CT/cdiI ECL .
Point mutations were introduced into cdiA-CT ECL using megaprimer PCR (Aiyar and Leis, 1993) .
Megaprimers were first generated using mutagenic forward primers: ECL-CT ( Arabinose-inducible cdiA-CT expression constructs were generated using plasmid pCH450 (Hayes and Sauer, 2003) . The cdiA-CT ECL and cdiA-CT EC16 coding sequences were amplified using ECL-CT-Kpn/Nco-for with ECL-CT-Xho-rev (5´ -TCC CTC GAG ACC ACT AGT CCT TAA TCC), and EC16-CT-Nco-for with EC16-CT-Xho-rev (5´ -TTT CTC GAG TTA TTT TAC CTT TAA ATC), respectively. The products were digested with NcoI/XhoI and ligated to plasmid pCH450. For in vivo immunity assays, compatible cdiI expression constructs were generated using plasmid pTrc99A
derivatives. The cdiI ECL gene was amplified with ECL-cdiI-Eco-for (5´ -GAT TAA GGA ATT CTG GTA TGT TTG G) and ECL-cdiI-Sac-rev (5´ -AGT GAG CTC TGT TTC AGT TGT TAA GAC) and ligated to pTrc99A using EcoRI and SacI restriction sites. The cdiI ECL gene was also amplified with ECL-cdiI-Ecofor and pET-Pst (5´ -CGG CTG CAG CAG CCA ACT CAG TGG) and ligated to plasmid pCH450 for the overproduction and purification of CdiI ECL -His 6 . The cdiI EC16 gene was amplified with EC16-virAKpn-for and EC16-virA-Xho-rev (5´ -TTT CTC GAG TTA TTG GGA ATC AAG GAT C) and ligated to plasmid pTrc-rhsI B (Koskiniemi et al., 2013) using KpnI and XhoI restriction sites. The cdiI ECL and cdiI EC16 genes were also subcloned into plasmid pCH450 to test immunity function in E. cloacae growth competitions.
The EC93-ECL chimeric CDI system was constructed by allelic exchange of the counterselectable pheS* marker from cosmid pCH10163 as described (Morse et al., 2012) . The cdiA-CT/cdiI ECL coding region was amplified with primers ECL-CT-chim-for (5´ -TCG CTG GCA CTG GTT GCC AGA GGT TG) and ECL-cdiI-chim-rev (5´ -TTA GTT GTT AAG ACT ATG ATA AAA ATC). An upstream cdiA EC93 homology region was amplified with primers DL1527 (5´ -GAA CAT CCT GGC ATG AGC G) and ECL-chim(OE)-rev (5´ -CAA CCT CTG GCA ACC AGT GCC AGC GAA TTA TTC TCA ACC GAG TTC CTA CCT G), and a downstream homology region amplified with primers ECL-chim(OE)-for (5 ´-GAT TTT TAT CAT AGT CTT AAC AAC TAA CCC AAA GGT TAG ACA CCA GAC C) and DL2368 (5´ -GTT GGT AGT GGT GGT GCT G). The three PCR products were combined by OE-PCR using oligonucleotides DL1527 and DL2368. The final DNA product (100 ng) was electroporated together with pCH10163 (300 ng) into E. coli strain DY378 cells (Thomason et al., 2007) and recombinants selected on yeast extract glucose-agar supplemented with 33 "g/mL chloramphenicol and 10 mM D/Lp-chlorophenylalanine.
Protein purification and crystallography
The CdiA-CT ECL /CdiI ECL -His 6 complex was overproduced from plasmid pET21K::cdiA-CT/cdiI ECL in either E. coli BL21 (DE3) Gold ( carried out with the HKL2000 suite (Otwinowski and Minor, 1997) , resulting in three 100% complete datasets with combined significant anomalous differences up to 4.6 Å resolution. Experimental phasing and initial model building was performed using AutoSol and Autobuild in PHENIX (Terwilliger et al., 2009) , in which six Se atoms were located per asymmetric unit. A high-resolution dataset was collected with a second P4 1 22 Se-Met-labeled crystal with a slightly smaller unit cell (85.25 Å ! 85.25 Å ! 74.91 Å) at 70 K at 1.00 Å and designated 'native' in Table 1 . Data reduction was carried out with the HKL2000 suite, resulting in a 100% complete dataset up to 2.4 Å. Non-optimal detector positioning during data collection necessitated the high-resolution limit of 2.4Å. The structure was solved via molecular replacement utilizing phenix.automr, and the final model obtained through iterative manual building in Coot and refinement with phenix.refine (Adams et al., 2010; Emsley and Cowtan, 2004; McCoy et al., 2007) . The final model includes residues 160 -235 of CdiA-CT ECL (numbered from Ala1 of the AENN motif) and residues 1 -141 of CdiI ECL with a final R work /R free (%) 18.3/23.7 (Table 1) . CdiA-CT ECL residues Leu160 -Lys163, His188 and loop L4 (residues Ser206 -Asn211) were modeled as alanines due to lack of observable side chain density. Additionally, residues Glu72, Lys73, Glu99 and His102 of CdiI ECL were modeled as alanines. Atomic coordinates and structure factors have been deposited in the Protein Data Bank (www.pdb.org) as PDB ID code 4NTQ.
Toxin-immunity binding and RNase assays
CdiA-CT/CdiI-His 6 complexes were denatured in binding buffer [20 mM sodium phosphate (pH 7.0, 150 mM NaCl, 10 mM "-mercaptoethanol] supplemented with 6 M guanidine-HCl, and CdiA-CT proteins isolated in the void volume during Ni 2+ -affinity chromatography (Aoki et al., 2010) . Toxins were refolded by dialysis against binding buffer. CdiI-His 6 proteins were purified by Ni 2+ -affinity chromatography under non-denaturing conditions as described . The isolated toxins and immunity proteins were dialyzed against reaction buffer and quantified by absorbance at 280 nm. Purified CdiA-CT and CdiI-His 6 protein were mixed at 10 "M final concentration in binding buffer and binding interactions assessed by co-purification during Ni 2+ -affinity chromatography as described (Aoki et al., 2010; Nikolakakis et al., 2012) . In vitro nuclease activity assays were conducted in binding buffer supplemented with 10 mM MgCl 2 . Ribosomes were isolated from S30 lysates of E. coli strain CH1944 by centrifugation at 100,000 !g for 4 hr at 4 °C. Ribosomes (10 "M) were incubated with purified CdiA-CT (1 "M) in binding buffer supplemented 10 mM MgCl 2 for 1 hr at 37 °C. Where indicated, CdiI-His 6 immunity protein was also included at 1 "M final concentration. Reactions were analyzed by denaturing electrophoresis on 50% urea -6% polyacrylamide gels in 1! Tris-borate-EDTA buffer. Gels were transferred to nylon membrane and hybridized to 5´-radiolabeled oligonucleotide (5´ -TAA GGA GGT GAT CCA ACC GCA), which is complementary to the 3´-end of E.
coli 16S rRNA. For primer extension analysis, ribosomes were isolated from E. coli CH10420 cells that lack the RsmE methyltransferase. Reactions were quenched with guanidinium isothiocyanate-phenol and rRNA extracted as described (Garza-Sanchez et al., 2006) . Primer extension was performed as previously described (Diner and Hayes, 2009 ) using 5´-radiolabeled oligonucleotide (5´ -GGT TCC CCT ACG GTT ACC TTG) as a primer.
CdiA-CT toxicity and in vivo nuclease activity was assessed in E. coli strain X90 (Table S2) harvested into an equal volume of ice-cold methanol, cells were collected by centrifugation and frozen at -80 °C. RNA was isolated from the frozen cell pellets using guanidine isothiocyanate-phenol and 10 "g of total RNA used for northern blot analysis as described (Garza-Sanchez et al., 2006) .
Growth competitions
E. cloacae inhibitor cells (CH11250 or CH11196) were co-cultured with target E. cloacae !cdiAI cells (CH11475) at a 10:1 ratio on LB-agar with 0.2% L-arabinose. Co-cultures were incubated at 37 °C for 4 hr and then cells harvested into 1! M9 salts for serial dilution and colony forming unit (CFU) enumeration on selective media. Immunity function was evaluated through expression of cdiI genes in targets from pCH450 constructs. Cross-species competitions were performed under the same conditions using E. coli strain CH10013 as targets. Immunity function was assessed in E. coli targets through cdi expression from pTrc constructs.
The chimeric EC93-ECL CDI system was expressed in E. coli EPI100 cells from cosmids pCH10445 and pCH10508. The CDI + inhibitors were mixed at a 1:1 ratio with E. coli CH10013 target cells in LB media and incubated at 37 °C with shaking in a baffled flask for three hours. Samples were taken periodically for enumeration of viable target cells as CFU/mL. E. coli EPI100 carrying cosmid pWEB-TNC (Epicentre) was used as a mock (CDI -) inhibitor and immunity function was assessed using plasmid pTrc expression constructs. Co-culture samples were harvested into an equal volume of icecold methanol for subsequent RNA analysis as described above.
